$Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia$

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lympho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2010-01, Vol.115 (3), p.489-495
Hauptverfasser:	Byrd, John C., Kipps, Thomas J., Flinn, Ian W., Castro, Januaro, Lin, Thomas S., Wierda, William, Heerema, Nyla, Woodworth, James, Hughes, Steve, Tangri, Shabnam, Harris, Sarah, Wynne, Dee, Molina, Arturo, Leigh, Bryan, O'Brien, Susan
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - blood Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Clinical Trials and Observations Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Disease-Free Survival Dose-Response Relationship, Drug Drug Resistance, Neoplasm - drug effects Female Hematologic and hematopoietic diseases Humans Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - metabolism Leukemia, Lymphocytic, Chronic, B-Cell - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Recurrence Rituximab Vidarabine - administration & dosage Vidarabine - adverse effects Vidarabine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!